Gap finder
Search review questions
Each row is one question a systematic review asked: who, what, compared with what, and which outcome, with the effect it found and how certain that is. Words match anywhere in the field.
1,751 questions in 147 reviews · Pain, Palliative and Supportive Care
current versionsNo studies 361 · 20.6%Ungraded 87 · 5%Very low 625 · 35.7%Low 367 · 21%Moderate 232 · 13.2%High 79 · 4.5%
Ungraded means an effect was reported without a GRADE rating; it is not a gap. No studies means the review found nothing to answer the question. The six categories are a display order, not a score.
| Question | Effect | Evidence | Status / GRADE |
|---|---|---|---|
Summary of findings: haloperidol vs olanzapine Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 1.9 | 1 study · 24 participants | Very low |
Summary of findings: haloperidol vs olanzapine Agitation within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs olanzapine Agitation between 24 and 48 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs olanzapine Adverse events including extrapyramidal effects · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: risperidone vs placebo Symptoms of delirium within 24 hoursa · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 0.76 | 1 study · 129 participants | Low |
Summary of findings: risperidone vs placebo Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 0.85 | 1 study · 111 participants | Low |
Summary of findings: risperidone vs placebo Agitation within 24 hoursc · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: risperidone vs placebo Agitation between 24 and 48 hoursc · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | 1 study · 111 participants | Low |
Summary of findings: haloperidol vs placebo Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 0.49 | 1 study · 123 participants | Low |
Summary of findings: risperidone vs placebo Adverse events including extrapyramidal effectsd · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 0.73 | 1 study · 111 participants | Low |
Summary of findings: lorazepam plus haloperidol vs placebo plus haloperidol Symptoms of delirium within 24 hoursa · terminally ill adults with severe delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 2.1 | 1 study · 50 participants | Very low |
Summary of findings: lorazepam plus haloperidol vs placebo plus haloperidol Symptoms of delirium between 24 and 48 hours · terminally ill adults with severe delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: lorazepam plus haloperidol vs placebo plus haloperidol Agitation within 24 hoursc · terminally ill adults with severe delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 1.9 | 1 study · 52 participants | Very low |
Summary of findings: lorazepam plus haloperidol vs placebo plus haloperidol Agitation between 24 and 48 hoursc · terminally ill adults with severe delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: lorazepam plus haloperidol vs placebo plus haloperidol Adverse events including extrapyramidal effectsd · terminally ill adults with severe delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | RR 0.7 | 1 study · 31 participants | Very low |
Summary of findings: haloperidol vs chlorpromazine Symptoms of delirium within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs chlorpromazine Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 0.37 | 1 study · 24 participants | Very low |
Summary of findings: haloperidol vs chlorpromazine Agitation within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs chlorpromazine Agitation between 24 and 48 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs placebo Agitation within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs chlorpromazine Adverse events including extrapyramidal effectsc · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 0.46 | 1 study · 24 participants | Very low |
Summary of findings: haloperidol vs lorazepam Symptoms of delirium within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs lorazepam Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | 1 study · 17 participants | Very low |
Summary of findings: haloperidol vs lorazepam Agitation within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs lorazepam Agitation between 24 and 48 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs lorazepam Adverse events including extrapyramidal effectsc · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | 1 study · 16 participants | Very low |
Summary of findings: lorazepam vs chlorpromazine Symptoms of delirium within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: lorazepam vs chlorpromazine Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 5.25 | 1 study · 19 participants | Very low |
Summary of findings: lorazepam vs chlorpromazine Agitation within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: lorazepam vs chlorpromazine Agitation between 24 and 48 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs placebo Agitation between 24 and 48 hoursc · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | 1 study · 123 participants | Low |
Summary of findings: lorazepam vs chlorpromazine Number of adverse events including extrapyramidal effectsc · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 7.12 | 1 study · 18 participants | Very low |
Summary of findings: haloperidol vs placebo Adverse events including extrapyramidal effectse · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | MD 0.79 | 1 study · 123 participants | Moderate |
Summary of findings: haloperidol vs risperidone Symptoms of delirium within 24 hoursa · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | 1 study · 126 participants | Low |
Summary of findings: haloperidol vs risperidone Symptoms of delirium between 24 and 48 hoursa · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | 1 study · 106 participants | Low |
Summary of findings: haloperidol vs risperidone Agitation within 24 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: haloperidol vs risperidone Agitation between 24 and 48 hours · terminally ill adults with delirium Drug therapy for delirium in terminally ill adults (2020) · Cochrane | no estimate extracted | NR | No studies |
Summary of findings: CBT vs AC Pain intensity at the end of treatment as measured by multiple scales including VAS, BPI, AIMS, numerical rating scale, MPI Higher scores indicate higher pain intensity · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 23 studies · 3235 participants | Moderate |
Summary of findings: CBT vs TAU Disability at the end of treatment as measured by multiple scales including AIMS, ODI, FIQ, MPI Higher scores indicate higher levels of disability · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 28 studies · 2524 participants | Low |
Summary of findings: CBT vs TAU Disability at · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 15 studies · 1581 participants | Low |
Summary of findings: CBT vs TAU Distress at the end of treatment as measured by multiple scales including BDI, CES‐D, SCL‐90R, HADS Higher scores indicate higher levels of distress · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 27 studies · 2559 participants | Moderate |
Summary of findings: CBT vs TAU Distress at · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 16 studies · 1757 participants | Moderate |
Summary of findings: CBT vs TAU Adverse events Higher scores indicate higher numbers of AEs · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 8 studies · 1314 participants | Very low |
Summary of findings: CBT vs AC Pain intensity at · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 16 studies · 2362 participants | Moderate |
Summary of findings: CBT vs AC Disability at the end of treatment as measured by multiple scales including RMDQ, AIMS Higher scores indicate higher levels of disability · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 19 studies · 2543 participants | Moderate |
Summary of findings: CBT vs AC Disability at · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 15 studies · 1919 participants | Low |
Summary of findings: CBT vs AC Distress at the end of treatment as measured by multiple scales including BDI, DASS and CES‐D Higher scores indicate higher levels of distress · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 24 studies · 3297 participants | Moderate |
Summary of findings: CBT vs AC Distress at · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 16 studies · 2363 participants | Moderate |
Summary of findings: CBT vs AC Adverse events Higher scores indicate higher numbers of AEs · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 3 studies · 689 participants | Very low |
Summary of findings: CBT vs TAU Pain intensity at the end of treatment as measured by multiple scales including VAS, BPI, AIMS, numerical rating scale, MPI Higher scores indicate higher pain intensity · Adults with chronic pain (excluding headache) Psychological therapies for the management of chronic pain (excluding headache) in adults (2020) · Cochrane | no estimate extracted | 29 studies · 2572 participants | Moderate |